Challenge: The Menarini Group’s commitment is focused on patients affected by cardiometabolic diseases, which is the main cause of deaths globally. In 2015, 75% of deaths resulting from cardiovascular diseases (CVDs) occurred in LMICs, where they were detected too late.
Aim: To increase patients’ access to CVD treatments, which is often hindered due to the unaffordability of treatments for a large portion of the population in LMICs.
Action: The objective is to fill in the gaps in terms of medicine accessibility according to Menarini’s portfolio, which includes antihypertensives, anti-diabetics and drugs for CVDs. By providing therapeutic solutions to patients, a real contribution can be given that improves their life expectancy.
Results: It is currently too premature to report results given the programme is in its early stages
for more information